P740 Efficacy and safety of vedolizumab in inflammatory bowel disease: Real-life experience

Muñoza, C González; Mesonero, Francisco; Bargalló, Ana; Clos, Ariadna; Aràjol, C; Gordillo, Jordi; Román, Antonio; Guardiola, Jordi; Navarro-Llavat, M; Bertoletti, Federico; Fernández, Clara Fernández; Domènech, Eugeni; García‐Planella, Esther

doi:10.1093/ecco-jcc/jjx180.867

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Study characteristics are described in Supplementary Table 6. 28 studies were performed in patients with IA; 18,19,26-28,30-36,47,49-51,55-57, 59-63,67,79,80,83 25 in patients with RA; 7,16,17,23,24,37,39,40,[42][43][44][45]53,54,58,66,68,70,[73][74][75][76][77][78]84 5 in patients with AS; 21,25,46,48,65 4 in patients with PsA; 41,64,71,81 4 in patients with UC; 22,69,72,82 2 in patients with IBD (with results reported separately for UC); 38,52 and one in patients with SpA. 29 Most studies were retrospective (n=37), while 28 were prospective and one was cross-sectional.…”

Section: Study Characteristicsmentioning

confidence: 99%

<p>Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review</p>

Luttropp¹,

Dalén²,

Svedbom³

et al. 2020

PPA

View full text Add to dashboard Cite

Purpose: To obtain an up-to-date overview of the measurement of patient experience of switching biologic treatment in patients with inflammatory arthritis (IA) or ulcerative colitis (UC). Secondary objectives included summarizing the types of patient-reported outcomes (PROs) used (if any), and related findings; and summarizing medical and non-medical reasons for treatment switch and/or discontinuation. Methods: A systematic literature review (SLR) was performed, searching Medline and Embase for relevant publications. Results: In total, 70 relevant publications were identified. While the majority of these reported reasons for switching and/or discontinuing treatment, only four provided information explicitly regarding patient-reported experience of switching biologic treatment. All four utilized ranking tools to assess patient experience of switching biologic treatment. The most common reason for switching and/or discontinuing treatment was loss of efficacy, while the least common reason was patient preference. Conclusion: Although the number of available treatments in IA and UC have increased, there is a sparsity of information regarding patient-reported experience of switching biologic treatment. Further research regarding patient preference and/or experience would benefit this therapeutic area and help guide treatment choices.

show abstract